In Depth 18 Jun 2025 From undruggable to oral therapy: The rise of STAT6 degraders Delve into the STAT6 degrader technology and what it could bring to inflammatory and allergic disease treatment. June 18, 2025 - 5 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 13 Dec 2024Finding new treatments for peanut allergy Individuals with peanut allergies are at constant risk of severe reactions, and this week, we talk about new treatments with Jessica Grossman of IgGenix. December 13, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Podcast 8 Dec 2023Can worms provide treatments for some diseases? U.S. company Holoclara is looking to tackle diseases through the development of worm-derived therapeutics. Allergic and autoimmune diseases were first described in the early 1900s, which Holoclara said is the same time that gut-resident worms such as the roundworm, Caenorhabditis elegans, were removed from people in industrialized countries. The company, led by CEO Andrea Choe, […] December 8, 2023 Share WhatsApp Twitter Linkedin Email
In Depth 9 Jun 2023 Enhancing canine wellness: The promise of immunotherapy for dogs Given that dogs are widely regarded as ‘man’s best friend’, it makes sense that we are constantly striving to find ways to improve canine health and extend their lives. One method that has been – and is still being – explored is the use of immunotherapy, which uses a dog’s own immune system to fight […] June 9, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 11 May 2023 Battling food allergies: emerging immunotherapies While for most individuals, picking a restaurant to dine at could simply be based on what they might be craving at the moment, for about one to five per cent of the world’s population, this is a well-thought-out decision that involves ensuring there wouldn’t be any cross-contamination in the food which is bound to trigger […] May 11, 2023 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 2 May 2023 The future of asthma treatment: is a cure possible? For around 300 million people in the world, whipping out their inhaler – a medical device that delivers medicine to the lungs to open up narrowed airways – before puffing medicine into their mouth, is a typical response to wheezing, worsened by an asthma attack. While inhalers offer momentary relief, it is, however, no cure. […] May 2, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2022 Allergy Therapeutics moves ahead with peanut and grass pollen allergy trials Allergy Therapeutics has announced the first subject has been dosed in the pivotal phase III G306 trial, to evaluate the efficacy and safety of Grass MATA MPL. Grass MATA MPL is Allergy Therapeutics’ short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate, which aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen. Grass […] December 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 19 Aug 2022 How re-engineering antibodies can prevent allergies The California startup IgGenix is aiming to re-engineer antibodies that mediate allergic responses into antibodies that can block this response. We spoke with IgGenix’s CEO Jessica Grossman and CTO Derek Croote to understand the potential of such a therapy. Allergies are overreactions of the immune system to foreign substances that are normally harmless. Worldwide, and […] August 19, 2022 - 9 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 From mugwort allergy to an effective vaccine? A research team at MedUni Vienna in Austria says it has discovered key mechanisms of allergy to pollen from the common weed mugwort, which could lay the foundation for the development of the world’s first vaccine. Mugwort (Artemisia vulgaris) poses a serious problem for some people with allergies in places where the plant is common […] June 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Apr 2021 DBV Battles Aimmune for Share of Peanut Allergy Treatment Market Last year, the FDA rejected DBV Technologies’ peanut allergy treatment and approved that of its rival Aimmune. After recent talks with the FDA and EMA, DBV has laid out a comeback plan that could carve it a niche in the peanut allergy treatment market. The French biotech firm DBV is coming back from a snub by […] April 14, 2021 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 May 2019 Top 10 Biotechs in Lausanne The Swiss city of Lausanne is perhaps best known as a hub of international sport, but what many outsiders may not realize is that it’s also one of Switzerland’s biggest biotech hubs. Many of the biotechs in the city are connected to the University of Lausanne (UNIL), as well as the renowned Swiss Federal Institute […] May 8, 2019 - 7 minutesmins - By David Cox Share WhatsApp Twitter Linkedin Email
News and Trends 18 Mar 2019 Shares Drop 40% as Allergy Therapeutics Announces Failed Phase III Trial Allergy Therapeutics has revealed that its immunotherapy for birch pollen allergy did not result in a significant symptom improvement when compared to a placebo. As a direct result of the announcement, the shares of Allergy Therapeutics on the London Stock Exchange dropped over 40% within two hours. The phase III trial enrolled 582 people across […] March 18, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email